A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated Urinary Tract Infections (Cutis)
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Cefepime
- Indications Urinary tract infections
- Focus Adverse reactions
- Sponsors AstraZeneca; Pfizer
- 25 Oct 2017 Status changed from recruiting to completed.
- 10 Oct 2017 Planned End Date changed from 2 Oct 2017 to 2 Nov 2017.
- 10 Oct 2017 Planned primary completion date changed from 2 Oct 2017 to 2 Nov 2017.